Skip to main content

Table 2 Results of single trial and direct comparison meta-analysis

From: Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: a systematic review and network meta-analysis

Treatment

Study

OS

PFS

ORR

Overall SAEs

RP

Heterogeneity I2(%)

  

HR(95%CI)

HR(95% CI)

OR(95% CI)

OR(95% CI)

OR(95% CI)

OS

PFS

ORR

SAE

RP

EP vs PC

[4,5,6]

0.85 (0.77–0.94)

0.66 (0.47–0.95)

1.0 (0.86–1.2)

1.2 (0.81–1.4)

0.48 (0.21–1.1)

0

0

59

0

27

PC-Cet vs PC

[7]

1.1 (0.84–1.4)

0.99 (0.8–1.2)

NR

1.2 (1.1–1.4)

0.56 (0.27–1.2)

     

UP vs NP

[8]

0.86 (0.35–2.1)

0.68 (0.35–1.3)

1.6 (0.53–5.1)

0.47 (0.29–0.76)

0.88 (0.12–6.6)

     

NP vs PP

[9]

1.7 (0.81–3.4)

1.6 (0.91–2.6)

1.4 (0.38–5.4)

1.9 (1.1–3.3)

5.7 (0.26–120.6)

     

SP vs NP

[10]

0.85 (0.49–1.5)

0.37 (0.15–0.94)

0.79 (0.31–2.0)

0.67 (0.50–0.88)

1.3 (0.32–5.0)

     

NP vs EP

[11]

0.93 (0.75–1.1)

NR

1.3 (0.82–1.9)

0.91 (0.81–1.0)

0.86 (0.50–1.5)

     

PC vs DP

[12]

1.0 (0.33–3.3)

1.1 (0.48–2.3)

0.67 (0.23–2.0)

0.67 (0.39–1.2)

4.7 (0.22–101.6)

     

PC vs GP

[12]

0.77 (0.34–1.8)

0.67 (0.3–1.5)

1.1 (0.40–3.0)

0.80 (0.45–1.4)

1.9 (0.17–22.5)

     

DP vs GP

[12]

0.65 (0.28–1.5)

0.72 (0.36–1.5)

1.7 (0.56–4.9)

1.2 (0.70–2.0)

0.34 (0.01–8.8)

     

MVP vs DP

[13]

1.2 (0.8–1.7)

1.2 (0.89–1.7)

0.64 (0.33–1.2)

1.8 (1.5–2.0)

0.67 (0.24–1.8)

     

SP vs DP

[14]

0.81 (0.39–1.7)

1.1 (0.63–1.9)

1.2 (0.52–2.8)

0.49 (0.35–0.68)

0.10 (0.31–3.2)

     

MVP vs IC

[15]

0.98 (0.74–1.3)

0.89 (0.69–1.1)

1.5 (0.95–2.5)

1.8 (1.5–2.0)

0.33 (0.06–1.6)

     

MVP vs PC

[15]

0.95 (0.72–1.3)

1.1 (0.82–1.4)

1.2 (0.71–1.9)

2.1 (1.8–2.4)

0.33 (0.06–1.6)

     

IC vs PC

[15]

1.1 (0.79–1.4)

1.1 (0.86–1.5)

0.75 (0.47–1.2)

1.2 (1.0–1.4)

1.0 (0.31–3.2)

     

PP vs EP

[16]

0.98 (0.79–1.2)

0.86 (0.71–1.0)

1.1 (0.81–1.6)

0.96 (0.85, 1.1)

0.68 (0.21–2.2)

     

PP vs PP-Cet

[17]

1.1 (0.58–2.0)

1.1 (0.62–1.8)

1.3 (0.54–3.3)

0.99 (0.74–1.3)

1.1 (0.32–3.6)

     
  1. Abbreviations: OS overall survival, PFS progression-free survival, ORR objective response rate, SAEs serious adverse events, RP radiation pneumonitis, HR hazard ratio, CI confidence interval, OR odds ratio, EP etoposide-cisplatin, PC paclitaxel-cisplatin/carboplatin, UP uracil/tegafur(UFT)-cisplatin, NP vinorelbine-cisplatin, PP pemetrexed-cisplatin/carboplatin, SP S-1-cisplatin, DP docetaxel-cisplatin, GP gemcitabine-cisplatin, MVP mitomycin-vindesine-cisplatin, IC irinotecan-carboplatin, Cet cetuximab, NR not reported
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us